Last reviewed · How we verify

NCT05555446

Bovine Colostrum to Prevent Absorption of Gluten

Suspended EARLY_PHASE1 Last updated 4 December 2024
What this trial tests

EARLY_PHASE1 trial testing Bovine colostrum in Celiac Disease in 10 participants. Suspended.

Timeline
22 September 2022
Primary endpoint
1 January 2025
1 January 2025

Quick facts

Lead sponsorMilky Way Life Sciences LLC
PhaseEARLY_PHASE1
StatusSuspended
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposetreatment
Enrollment10
Start date22 September 2022
Primary completion1 January 2025
Estimated completion1 January 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Milky Way Life Sciences LLC

Who can join

Adults 18 to 75, any sex, with Celiac Disease or Gluten Sensitivity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the use of hyperimmune bovine colostrum to reduce gluten absorption. A double-blind, cross-over study will be performed in which persons who are following a strict gluten-free diet will be challenged with oral gluten with or without the bovine colostrum.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Evolution in coeliac disease diagnosis and management.
    Tye-Din JA. · · 2024 · cited 8× · PMID 38957478 · DOI 10.1002/jgh3.13107

Verify or expand the search:

Other trials of Bovine colostrum

Trials testing the same drug.

Other recruiting trials for Celiac Disease

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05555446.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing